Multiple studies have revealed that aberrant upregulation of the methyltransferases METTL1 and WDR4 is significantly associated with progressive tumour stage and aggressive vascular infiltration, and poor clinical outcomes in HCC patients, highlighting their potential as prognostic biomarkers and therapeutic targets.49 The gene discussed is METTL1; the disease is hepatocellular carcinoma.